Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2002

View Archived Issues

LY-451395 enters the brain following multiple oral doses in man

Favorable pharmacokinetic profile described for new camptothecin analogue DRF-1042

Escalating oral and i.v. doses of sabiporide tested in humans for safety and PK/PD profile

New data on natalizumab presented at ACTRI/ECTRI conference

Zenapax may improve the therapeutic effect of interferon in multiple sclerosis

Quetiapine found to improve cognitive function in first-episode psychosis

No antiplatelet effects found for a supratherapeutic dose of valdecoxib in healthy subjects

Potential reported for RWJ-67657 in the management of sepsis and cytokine-mediated disorders

Acyline is safe and decreases serum gonadotropin and testosterone levels in humans

New data on the antiangiogenic effects of endostatin against advanced solid tumors

Cilomilast proven effective in improving lung function of smoking and nonsmoking COPD patients

Beneficial effects on chronic lung rejection reported for switching from ciclosporin to tacrolimus

Cozaar reduces the risk of ESRD in patients with type 2 diabetes, nephropathy and hypertension

Global collaboration signed for potential breakthrough diabetes therapy

Genmab's HuMax-CD4 enters phase IIb trial in psoriasis

Endovasc spin-off company will develop Liprostin

Access Oncology obtains rights to develop and market antitumor alkylphosphocholine

Hybridon and Aegera collaborate to develop antisense drug targeting XIAP gene

5-HT6 ligands claimed in the patent literature by Wyeth

Urotensin-II receptor antagonists and potential uses described in recent patent

Novel CRF1 antagonists identified at Bristol-Myers Squibb

Synthesis, activity and use of glycine uptake inhibitors reported

Recent patent covers new human PPAR activators discovered at GSK

GSK designs new series of antiangiogenic agents

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....